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Objectives
Across Europe, almost a third of individuals infected with HIV do not enter health care until late in
the course of their infection. Surveillance to identify the extent to which late presentation occurs
remains inadequate across Europe and is further complicated by the lack of a common clinical
definition of late presentation. The objective of this article is to present a consensus definition of late
presentation of HIV infection.
Methods
Over the past year, two initiatives have moved towards a harmonized definition. In spring 2009, they
joined efforts to identify a common definition of what is meant by a ‘late-presenting’ patient.
Results
Two definitions were agreed upon, as follows. Late presentation: persons presenting for care with a
CD4 count below 350 cells/mL or presenting with an AIDS-defining event, regardless of the CD4 cell
count. Presentation with advanced HIV disease: persons presenting for care with a CD4 count below
200 cells/mL or presenting with an AIDS-defining event, regardless of the CD4 cell count.
Conclusion
The European Late Presenter Consensus working group believe it would be beneficial if all national
health agencies, institutions, and researchers were able to implement this definition (either on its
own or alongside their own preferred definition) when reporting surveillance or research data
relating to late presentation of HIV infection.
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Background
Across Europe, almost one-third of individuals infected
with HIV do not enter health care until late in the course of
their infection [1,2]. Despite attempts to encourage earlier
testing for HIV, this situation has remained stationary for
several years without evidence of improvement. Late
presentation for care is harmful to the infected person
[3–5] is more costly [6] and is harmful to society [7].
Surveillance to identify the extent to which late presenta-
tion occurs is therefore crucial and remains inadequate
across Europe, and is further complicated by the lack of a
common clinical definition of late presentation.
In untreated HIV-infected persons, the risk of developing
an AIDS-defining condition increases exponentially as the
CD4 cell count drops, being particularly high in those with
a CD4 count o200 cells/mL [8,9]. The longer therapy is
delayed when clinically indicated, the poorer the patient
outcome [10]. Recent guidelines [from the European AIDS
Correspondence: Dorthe Raben, HIV in Europe Secretariat, Copenhagen HIV
Programme, University of Copenhagen, Panum Institute – Building 21.1,
Blegdamsvej 3B, 2200 Copenhagen N, Denmark. Tel: 1 45 35 45 57 82; fax:
1 45 36 47 33 40; e-mail: mailto:dra@cphiv.dk
*The contribution of each member of the European Late Presenter Consensus
working group is described at the end of the manuscript.
DOI: 10.1111/j.1468-1293.2010.00857.x
r 2010 British HIV Association HIV Medicine (2011), 12, 61–64
61
Clinical Society (EACS), World Health Organization (WHO)
Europe, International AIDS Society (IAS) and British HIV
Association (BHIVA)] advocate antiretroviral therapy (ART)
for all untreated persons with a CD4 count o350cells/mL,
and for some patient groups with a higher CD4 cell count
[11–15]. Recently, it has been suggested that HIV may also
accelerate the course of various end-organ diseases, such as
cardiovascular disease, renal disease and liver disease, and
may increase the risk of contracting non-AIDS-defining
malignancies [16,17]. This suggestion was initially sup-
ported by data from the SMART trial, which found that
those interrupting ART had higher rates of these diseases
than those who remained on ART, but a strong link
between the CD4 cell count and many non-AIDS diseases
has also been seen in several observational studies [17].
These diseases are more common than AIDS diseases at
CD4 counts higher than 350 cells/ml [18].
The process of reaching a consensus of the definition of
a late presenter
In the literature, more than 20 different definitions have
been cited for a late presenter [19]. A common definition
would be helpful to more effectively manage late presenta-
tion of HIV disease across Europe and elsewhere. It would
also facilitate cross-country or regional comparisons, and
allow investigation of temporal trends after targeted
interventions. Of note, health policy is a European Union
(EU) member-state matter and not defined at the EU level;
this in part explains why divergent definitions have emerged
in various countries across Europe. Over the past year, two
initiatives have moved towards a harmonized definition. In
spring 2009, they joined efforts to identify a common
definition of what is meant by a ‘late-presenting’ patient.
The ‘Late presentation for HIV treatment in Europe’
programme was initiated in November 2008 in Glasgow
and culminated in March 2009 with a 2-day meeting on the
challenges of late presentation for HIV treatment in Europe.
The project focused on different aspects of late presentation
[20]. The group highlighted the need for a common
definition of late presentation.
The HIV in Europe initiative provides a European
platform for exchange and activities to encourage early
diagnosis and earlier care of HIV-infected patients across
Europe (www.hiveurope.eu). The initiative has since 2007
gathered key European constituencies (civil society, health
professionals and health policy makers) to discuss the
prevailing obstacles to earlier diagnosis of HIV infection.
As the HIV in Europe initiative focuses on attempts to
ensure that HIV-infected patients enter care earlier in the
course of their infection than is currently the case, the use
of diverse definitions of late presentation was already
identified as a major limitation in 2007 when attempting to
obtain a precise estimate of the size of the problem, and
when attempting to understand trends in this estimate over
time.
The consensus definition was reached in October 2009
and presented at the HIV in Europe 2009 Conference in the
Nobel Forum in Stockholm and at the EACS Conference in
Cologne in November 2009, where the consensus definition
appeared in several presentations [21,22].
The consensus definition of late presentation
for HIV care
As a premise for the definition, it was agreed that, while the
definition should be valid for identifying persons at
particularly increased risk of clinical disease progression,
it should also help to improve surveillance and satisfy
public health needs.
Two definitions were agreed upon, as follows.
 Late presentation: Persons presenting for care with a
CD4 count below 350 cells/mL or presenting with an
AIDS-defining event, regardless of the CD4 cell count.
 Presentation with advanced HIV disease: Persons pre-
senting for care with a CD4 count below 200 cells/mL or
presenting with an AIDS-defining event, regardless of
the CD4 cell count.
The term ‘late presentation’ should be used to refer to all
HIV-infected people who enter care at a stage of their
disease where current guidelines suggest that they are
unable to fully benefit from ART. In contrast, the term
‘presentation with advanced HIV disease’ should be
reserved for the subgroup of these late presenters who
are additionally at greater imminent risk of severe disease
and death. As such, patients with a CD4 counto200 cells/mL
will meet both criteria and will be both ‘late presenters’ and
‘presenters with advanced HIV disease’. Furthermore, any
person with an AIDS-defining condition will also meet
both criteria, regardless of his/her CD4 cell count.
Of note, the term ‘presentation for care’ means attendance
at a health care facility that is able to monitor progression
of HIV infection and initiate appropriate medical care,
including ART, as appropriate. Diagnosis of HIV infection
alone does not signify presentation for care. It is recognized,
and highly important to ensure, that earlier diagnosis of
HIV infection is linked to appropriate access to care.
Although not necessary for the classification of late
presenters, it is advisable to repeat the CD4 cell count
because of laboratory variability in its measurement, and
the fact that some individuals with certain conditions (e.g.
acute HIV infection, other ongoing viral infections and
pregnancy) or on certain treatments (e.g. anti-cancer and
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other types of chemotherapy with bone marrow suppres-
sive potential) may experience a temporary drop in CD4
cell count. If such a confirmatory CD4 cell count
measurement is performed, both measurements should be
below the threshold for the patient to fulfil the definition.
Discussion and conclusions
The consensus definitions of persons presenting late for
HIV care and presenting with advanced HIV diseases given
in this paper will hopefully end the long-standing debate
and the subsequent confusion regarding what is actually
meant by a ‘late presenter’. Such a central concept in public
health is best served when a common definition exists. A
similar definition has recently been proposed by a group of
UK investigators [23], and hence this report confirms that a
consensus has been reached – in a parallel process – also
on a European level. Europe-wide consensus on this issue is
critical in formulating a continent-wide response to this
public health crisis.
Current guidance on the use of ART is of utmost
importance in our consensus definition of a late presenter.
Until 2007, ART was recommended to be deferred in
asymptomatic persons until their CD4 count reached
200 cells/mL [24], but the guidelines then changed when
multiple studies demonstrated that persons living with HIV
and with a current CD4 count in the range of 200–
350 cells/mL remained at significant risk of contracting
opportunistic diseases [25, 26]. The findings from the
SMART trial strongly supported this policy of initiating
therapy in people with CD4 counto350 cells/mL. Therefore,
initiation of ART when the CD4 count nears 350 cells/mL
would reduce the incidence of such events. Serious non-
AIDS events are observed at a higher incidence than AIDS
events in persons living with CD4 counts 4350 cells/mL,
particularly among those with an elevated underlying risk
of such events [18, 27].
The December 2009 Department of Health and Human
Services Antiretroviral (ARV) Guidelines for Adults and
Adolescents recommend starting ARV therapy for patients
with a CD4 count o500 cells/mL [28]. This controversial
recommendation has not received general support across
Europe at the present time. However, while our proposed
threshold value of 350 cells/mL corresponds to the level at
which ART is currently recommended in Europe, our
proposed definition will not automatically change if future
European guidelines change. Even if there is shown to be a
relative benefit of starting ART at higher levels than at a
CD4 count of 350 cells/mL (a point currently disputed), it is
not evident that the definition of late presentation should
change. This is because of the low risk of disease
progression in people with CD4 counts 4350 cells/mL and
the fact that the time from infection to, for example, a CD4
count o500 cells/mL is relatively short, diluting the
concept of ‘late presentation’ as a public health issue. The
consensus group will reconvene to reconsider the issue at a
time when (if ever) guidelines are consistently recommend-
ing starting ART earlier.
The definitions of ‘late presentation’ and ‘presentation with
advanced HIV disease’ can be used in very diverse settings
and for many purposes. It provides a unified way to define
the problem, thereby targeting appropriate interventions. It
will permit further studies to be conducted across the
European continent to determine the size of the population at
risk, and to identify vulnerable groups and risk factors for
those patients with HIV infection presenting late for care. It
will also facilitate studies of the social and medical barriers
that may currently be limiting access to health care in
different European countries, and studies on access to ART
for late presenters across the continent. The definitions
should also be viewed as an instrument that enables ongoing
monitoring, and as such can be used to evaluate interven-
tions aimed at reducing the number of late presenters.
We believe it would be beneficial if all national health
agencies, institutions and researchers were able to imple-
ment this definition (either on its own or alongside their
own preferred definition) when reporting surveillance or
research data relating to late presentation of HIV infection.
In order to achieve this, these agencies and institutions
must ensure adequate capture of data on both the CD4 cell
count and presence of AIDS at presentation. Such moves
will facilitate comparisons between countries and assess-
ment of trends over time.
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